Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status approved; investigational; withdrawn
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 17205-205; 59572-215; 68554-0011; 82991-205; 59572-220; 17337-0301; 59572-210; 59572-205; 63818-0424
UNII 4Z8R6ORS6L
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coordination abnormal17.02.02.004--Not Available
Coronary artery disease24.04.04.006; 02.02.01.0010.000723%Not Available
Cough22.02.03.001--
Crohn's disease10.02.01.005; 07.08.01.0150.001784%Not Available
Cushingoid05.01.01.002; 24.08.02.004; 19.07.03.001; 14.11.01.0060.000241%
Cyanosis24.03.01.007; 22.02.02.007; 23.06.04.005; 02.11.04.004--
Cyst16.02.02.002; 08.03.05.0010.000241%Not Available
Deafness04.02.01.0010.000844%Not Available
Death08.04.01.0010.063654%
Decubitus ulcer23.03.11.0060.000362%Not Available
Dehydration14.05.05.0010.002942%
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.0010.001085%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000362%Not Available
Demyelination17.16.02.001--Not Available
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative10.01.01.004; 23.03.07.0010.000530%
Diabetes mellitus14.06.01.001; 05.06.01.0010.001688%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000241%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Disability26.01.01.003--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.0070.022327%
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.0040.000651%Not Available
Drug interaction08.06.03.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene